CARGO Therapeutics (CRGX) and The Competition Critical Analysis
by Mitch Edgeman · The Markets DailyCARGO Therapeutics (NASDAQ:CRGX – Get Free Report) is one of 295 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare CARGO Therapeutics to related businesses based on the strength of its profitability, risk, valuation, analyst recommendations, earnings, dividends and institutional ownership.
Valuation and Earnings
This table compares CARGO Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CARGO Therapeutics | N/A | -$98.15 million | -0.40 |
| CARGO Therapeutics Competitors | $580.32 million | -$35.20 million | -21,849.85 |
CARGO Therapeutics’ competitors have higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of current ratings and price targets for CARGO Therapeutics and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CARGO Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
| CARGO Therapeutics Competitors | 1698 | 4995 | 12985 | 253 | 2.59 |
CARGO Therapeutics currently has a consensus target price of $30.33, indicating a potential upside of 48.04%. As a group, “Biological products, except diagnostic” companies have a potential upside of 59.55%. Given CARGO Therapeutics’ competitors higher probable upside, analysts plainly believe CARGO Therapeutics has less favorable growth aspects than its competitors.
Profitability
This table compares CARGO Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CARGO Therapeutics | N/A | -50.68% | -38.69% |
| CARGO Therapeutics Competitors | -4,959.69% | -159.98% | -43.01% |
Insider and Institutional Ownership
93.2% of CARGO Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 1.4% of CARGO Therapeutics shares are held by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
CARGO Therapeutics beats its competitors on 7 of the 12 factors compared.
About CARGO Therapeutics
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.